PD-1 expression
|
Bladder Cancer
|
PD-1 expression
|
Bladder Cancer
|
cisplatin Sensitive: C2 – Inclusion Criteria
|
cisplatin Sensitive: C2 – Inclusion Criteria
|
PD-1 expression
|
Urothelial Cancer
|
PD-1 expression
|
Urothelial Cancer
|
pembrolizumab + GSK3359609 Sensitive: C3 – Early Trials
|
pembrolizumab + GSK3359609 Sensitive: C3 – Early Trials
|
PD-1 expression
|
RCC
|
PD-1 expression
|
RCC
|
nivolumab Sensitive: C3 – Early Trials
|
nivolumab Sensitive: C3 – Early Trials
|
PD-1 expression
|
RCC
|
PD-1 expression
|
RCC
|
toripalimab Sensitive: C3 – Early Trials
|
toripalimab Sensitive: C3 – Early Trials
|
PD-1 expression
|
Merkel Cell Carcinoma
|
PD-1 expression
|
Merkel Cell Carcinoma
|
Immunotherapy Sensitive: C3 – Early Trials
|
Immunotherapy Sensitive: C3 – Early Trials
|
PD-1 expression
|
Melanoma
|
PD-1 expression
|
Melanoma
|
toripalimab Sensitive: D – Preclinical
|
toripalimab Sensitive: D – Preclinical
|